One of the components of the Global Fund’s evaluation strategy is a system of country reviews conducted with partner organisations. The reviews will assess (1) disease outcomes and impact; (2) the contribution of the Global Fund to these outcomes and impacts; and (3) what factors helped to bring about the changes in outcomes and impact. The last item is referred to by researchers as “causation.”
Changes to the charter of the Office of the Inspector General (OIG) adopted by the Global Fund Board specify that when the OIG conducts country audits, it will not evaluate programme impact.
The Global Fund's new Partnership Strategy includes an accountability framework to enable the Global Fund and its partners to assess the effectiveness of their partnerships by measuring the ability to deliver results on the ground.
The Global Fund Board approved the new Partnership Strategy at its meeting last month in Addis Ababa.
By 30 November 2009, programmes supported by the Global Fund were providing antiretroviral (ARV) treatment to 2.5 million people living with HIV, an increase of 25% compared to 2008. Global Fund-supported programmes were also providing directly observational therapy short course (DOTS) to 6.0 million people with TB, an increase of 30%; and had distributed 104 million insecticide-treated mosquito bed nets, an increase of 49%.
According to the Global Fund's Technical Review Panel (TRP), performance frameworks included in proposals submitted to the Fund continue to be inadequate. This is one of the observations contained in the "Report of the Technical Review Panel and the Secretariat on Round 9 Proposals," a document that was submitted to the recent Global Fund Board meeting in Addis Ababa.
The Global Fund has established a new "expanded funding" window for CCMs. The new window allows a CCM to apply for more than $50,000 a year in funding providing it submits a two-year workplan with measurable targets. (All references in this article to CCMs apply also to Sub-CCMs and Regional Coordinating Mechanisms.)